SynthesisHuman vaccines & immunotherapeutics2015
Immune response to Hepatitis B vaccine in patients with celiac disease: A systematic review and meta-analysis.
Synthesis in Human vaccines & immunotherapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Viruses and celiac disease: what do we know ?Clinical and experimental medicine · 2023Pooled it
- The emerging role of the gut microbiota in vaccination responses.Gut microbes · 2025Review
- No Increased Risk of Hepatitis B Virus Infection in Patients with Celiac Disease: A Population-Based Study.Digestive diseases and sciences · 2025Article
- Viral infections in celiac disease: what should be considered for better management.Clinical and experimental medicine · 2024Review
- Vaccine Efficacy and Safety in Patients with Celiac Disease.Vaccines · 2024Review
- Vaccinomics and adversomics: key elements for a personalized vaccinology.Clinical and experimental vaccine research · 2024Review
- Immune response to hepatitis B vaccine among children under 5 years in Africa: a meta-analysis.Tropical medicine and health · 2024Review
- Humoral immune response to COVID-19 infection or vaccination among celiac disease patients.Central-European journal of immunology · 2022Article
- Article
- Association between Elevated TGA-IgA Titers and Older Age at Diagnosis with Absence of HBV Seroconversion in Celiac Children.Vaccines · 2021Article
- Vaccinations and Immune Response in Celiac Disease.Vaccines · 2020Review
- Factors That Influence the Immune Response to Vaccination.Clinical microbiology reviews · 2019Review
- Coeliac disease: beyond genetic susceptibility and gluten. A narrative review.Annals of medicine · 2019Review
- Exploring the relationship between environmental enteric dysfunction and oral vaccine responses.Future microbiology · 2018Review
- To screen or not to screen? Celiac antibodies in liver diseases.World journal of gastroenterology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is debated whether patients with celiac disease (CD) have non-protective antibody responses to HBV vaccination more frequently than non-affected subjects. To perform a literature review and meta-analysis on protective response to HBV vaccination in CD patients. RCTs and observational controlled studies were eligible. Outcome of interest was an anti-HBs (HBsAb) titer ≥ 10 IU/L after last vaccine dose. Comparative index was rate ratio (RR). Heterogeneity between studies was addressed and funnel plots were analyzed. Meta-regression models were applied to investigate effect size due to study-specific variables. Twelve retrospective studies on a total of 1,447 participants and 4 prospective studies on 184 subjects were selected. The RR was 0.732 (95% C.I.: 0.664-0.808) and 0.777 (95% C.I.: 0.629-0.960) in the prospective and retrospective studies, respectively. The I(2), indicating heterogeneity, was 51.1% in retrospective, 39.8% in prospective studies. Non-protective antibody responses occurred more frequently in patients than controls. Due to limitations in the available studies, additional trials to evaluate post-vaccination HBsAb titer in CD patients are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.